The LRG is here to help, join our community of patients, caregivers and specialists!
We have the latest in GIST news and research to help manage your treatment!
We are accepting applications to be listed among our GIST Specialists.
The Latest News from the Life Raft Group
2011 Update – Clinical trial results published open access in Cancer Immunology Immunotherapy. “. . . Interim analysis of eight patients demonstrated significant induction of IFN-γ-producing-CD8+, -CD4+, -NK cell, and IFN-γ-producing-tumor-infiltrating-lymphocytes, signifying significant Th1 response and NK cell activation. After a median follow-up of 3.6 years, complete response (CR) + partial response (PR) = 100%, overall survival = 100%, one patient died of […]
A French phase I clinical trial, combining Gleevec + interleukin 2 (IL-2) should open in April 2007 at the Institute Gustave Roussy in Villejuif, France. The aim of this study, organized by a team of Professor Laurence Zitvogel’s, is to evaluate the efficacy as well as the toxicity of this medicinal combination in the treatment of various cancers, including GIST, but also to identify the presence and the action of Interferon Killer Dendritic Cells (IKDCs) in humans.
In this month’s March 2007 newsletter, Estelle LeCointe, the director of Association Française des Patients du GIST: Ensemble contre le GIST, has shared the story of the work of Professor Laurence Zitvogel. Professor Zitvogel and her colleagues are engaged in a project combining Gleevec and immunotherapy. It has been very interesting to watch this work evolve over the last few years. This research has culminated in the discovery of a new type of immune cell (in mice) and is poised to enter clinical trials in 2007.